Details for New Drug Application (NDA): 212693
✉ Email this page to a colleague
The generic ingredient in ERYTHROMYCIN is erythromycin stearate. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin stearate profile page.
Summary for 212693
Tradename: | ERYTHROMYCIN |
Applicant: | Zydus Lifesciences |
Ingredient: | erythromycin |
Patents: | 0 |
Pharmacology for NDA: 212693
Physiological Effect | Decreased Sebaceous Gland Activity |
Medical Subject Heading (MeSH) Categories for 212693
Suppliers and Packaging for NDA: 212693
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
ERYTHROMYCIN | erythromycin | TABLET;ORAL | 212693 | ANDA | Zydus Pharmaceuticals USA Inc. | 70710-1047 | 70710-1047-1 | 100 TABLET, FILM COATED in 1 BOTTLE (70710-1047-1) |
ERYTHROMYCIN | erythromycin | TABLET;ORAL | 212693 | ANDA | Zydus Pharmaceuticals USA Inc. | 70710-1047 | 70710-1047-3 | 30 TABLET, FILM COATED in 1 BOTTLE (70710-1047-3) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 250MG | ||||
Approval Date: | Mar 7, 2023 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 500MG | ||||
Approval Date: | Mar 7, 2023 | TE: | AB | RLD: | No |
Complete Access Available with Subscription